Open AccessAbsence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir
Author(s) -
Oche Agbaji,
Maxwell O Akanbi,
Ihedinachi Otoh,
PA Agaba,
Rolake Akinsola,
V.O. Okolie,
Placid Ugoagwu,
Aliyu Babadoko,
Adewumi Adediran,
Finomo O Finomo,
Jonah O Abah,
Haruna M Muktar,
Alani S Akanmu
Publication year - 2019
Publication title -
nigerian postgraduate medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.261
H-Index - 19
ISSN - 1117-1936
DOI - 10.4103/npmj.npmj_75_19
Subject(s) - abacavir , nigerians , medicine , human leukocyte antigen , hla b , group b , hla b antigens , immunology , human immunodeficiency virus (hiv) , viral load , antigen , antiretroviral therapy , political science , law
The presence of human leukocyte antigen (HLA) B*57:01 allele predicts hypersensitivity reaction (HSR) to abacavir (ABC), a nucleoside reverse-transcriptase inhibitor used for human immunodeficiency virus (HIV) treatment. However, the prevalence of this allele amongst Nigerians with HIV is yet to be established. We aimed to determine the prevalence of HLA-B*57:01 allele amongst Nigerians with HIV infection.